Form D · Pharmaceuticals
Immunovant, Inc.
New York, NY · CIK 0001764013
Offering snapshot reported Jan 21, 2025 · SEC filing
- Reported sold
- $450M Offering amount: $450M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 15, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 21, 2025 | Initial | $450,000,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-535843
Source: Form D, filed Jan 21, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eva Renee Barnett | Executive |
| Andrew Fromkin | Director |
| Michael Geffner | Executive |
| Melanie Gloria | Executive |
| Douglas Hughes | Director |
| Bill Macias | Executive |
| George Migausky | Director |
| Atul Pande | Director |
| Pete Salzmann | Director, Executive |
| Jay Stout | Executive |
| Frank Torti | Director |
| Christopher Van Tuyl | Executive |
| Eric Venker | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
320 West 37 Th Street
New York, NY, 10018
New York, NY, 10018